Will new autoimmune drugs address cost concerns? December 27, 2016 By Erin Bastick PharmD Find out what’s in the drug pipeline for autoimmune disease. Are payers optimistic about biosimilars’ savings? December 07, 2016 By Erin Bastick As more biosimilars are approved, plans and PBMs will continue to evolve their strategies regarding coverage and formulary management of these new medications. Five things physicians don’t know about biosimilars November 14, 2016 By Tracey Walker Awareness of biosimilars is high, but there are some gaps to be filled, according to a Biosimilars Forum study. Why Remicade biosimilar sales will grow in the U.S. Two new biosimilar announcements are expected to increase the uptake of the biosimilar infliximab to Johnson & Johnson’s Remicade for rheumatoid arthritis, Crohn’s disease, and other inflammatory conditions. Will docs prescribe the new RA biosimilars? While FDA recently approved two new biosimilars for rheumatoid arthritis and other inflammatory diseases, questions remain about how quickly physicians and patients will embrace the new drugs. Biosimilars and interchangeable biologics: News to watch October 06, 2016 By Aubrey Westgate Biosimilars in the United States are slowly gaining traction, but widespread confusion and legal barriers remain. Five specialty pharmaceutical trends to watch October 05, 2016 By Aubrey Westgate Approvals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar. FDA approves biosimilar to Humira FDA’s pace of biosimilar approvals is picking up, as it approved two major drugs for rheumatoid arthritis and other inflammatory diseases in the past month. FDA approves etanercept biosimilar for psoriasis, psoriatic arthritis September 21, 2016 By Lisette Hilton The FDA approved the biosimilars Erelzi for plaque psoriasis and Enbrel for psoriatic arthritis. Predictions for biosimilars: How market access will play out Early planning to craft a comprehensive real-world evidence generation strategy can help support the real-world safety and effectiveness of biosimilars.